Hangzhou Just Biotherapeutics (HJB) held the grand opening ceremony for its R&D Center and Manufacturing Facility. Around 200 guests including business partners, investors and representatives from pharmaceutical companies were present to witness this historical moment.
"HJB has reached another important milestone,” said Jonathan Y. Zhao, Founder and CEO of HJB, during a speech at the opening ceremony. “This is a great step towards our mission of expanding global access to biotherapeutics. We will further leverage the 3rd-generation biologics platform to develop and manufacture high quality biologics for patients around the world."
Jonathan Y. Zhao, Jim Thomas and two other senior executives from Amgen co-founded Just Biotherapeutics in Seattle in 2015. Subsequently, its sister company, HJB, was established in China in August 2016. So far, both companies employ nearly 200 scientists and engineers.
Over the past two years, HJB has secured a total of USD 67 million in financing from Lilly Asia Ventures, ARCH Venture Partners, Temasek, Taikang, HEDA and other investors. HJB completed the 140,000 sq.ft R&D Center and GMP Manufacturing Facility which will supply the global market with clinical and commercial product.